The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
Open accessPublished version of a preprint
Abstract
A decoy to neutralize SARS-CoV-2: Many efforts to develop therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the interaction between the spike protein, which decorates the surface of the virus, and its host receptor, human angiotensin-converting enzyme 2 (hACE2). Linsky et al. describe a de novo design strategy that allowed them to engineer decoy proteins that bind to the spike protein by replicating the hACE2 interface. The best decoy, CTC-445, bound with low nanomolar affinity, and selection of viral mutants that decrease binding is unlikely because this would also affect binding to hACE2. A bivalent version of CTC-445 bound even more tightly, neutralized SARS-CoV-2 infection of cells, and protected hamsters from a SARS-CoV-2 challenge. The stable decoy has the potential for respiratory therapeutic delivery. Science , this issue p. 1208
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Design and characterization of de novo ACE2 decoys. (A) ACE2 (gray) and its binding motifs (H1 19-52, orange; H2 55-84, green; EE3 346-360, blue) in complex with SARS-CoV-2 RBD (pink). Three starting structures were simultaneously used as targets (see main text); 6VW1 is shown. (B) De novo secondary structure elements (magenta) were computationally generated to stabilize H1, H2, and EE3. Seven combinations of secondary structure elements were considered. Circles are α-helices, triangles are β-sheets, filled circles are helices oriented forward, and empty circles are helices oriented backward. We used Rosetta to generate fully connected backbones (using the “protein_mimic_designer” algorithm) and amino acid sequences predicted to fold into the target structure. In all cases, the binding interface of ACE2 with the SARS-CoV-2 RBD was preserved intact (see the materials and methods). (C) Automatic computational filtering based on eight metrics selected the best candidates. The RMSD of the binding motifs to ACE2 was also used as a quality check. The dots indicate the mean computational score for each design scored against the three target RBD structures. Designs selected for experimental testing are shown in black. Our best design, CTC-445, is shown in red. The blue boxes indicate the filtering thresholds (see the materials and methods). (D) Designs that passed filtering were subjected to biased forward folding simulations (see the materials and methods), here shown for CTC-445, including the unsalted biased simulation (brown), the native-salted simulation (orange), and relaxation (blue). (E) The top 196 designs were selected for yeast display screening using a combination of Rosetta score per residue, the ddG Rosetta filter, and the folding simulations (see the materials and methods). The designs were individually assessed for specific binding to SARS-CoV-2 spike RBD (Fc fusion, 200 nM). The plot for CTC-445 is shown. (F) CTC-445 was recombinantly expressed and purified by affinity chromatography (see the materials and methods). Analytical size exclusion chromatography (SEC) for CTC-445 revealed the presence of oligomeric species. (G and H) CTC-445 was optimized by directed evolution and rational combination of the observed favorable mutations (G), leading to CTC-445.2 (SEC), which is mainly monomeric in solution (H) and ~1000× more potent to compete with ACE2 than its parent [see (G)]. We further optimized the potency of our molecule by generating a bivalent version named CTC-445.2d. (I) Potency of designs to outcompete binding of SARS-CoV-2 RBD to ACE2, as measured by competition enzyme-linked immunosorbent assay (ELISA) using a constant concentration of 0.4 nM ACE2. (J) Timeline of the de novo protein design and optimization pipeline. Timewise, green indicates phases that we believe were performed optimally, red indicates those that can potentially be avoided in future efforts, and yellow indicates phases that can potentially be expedited by using more advanced and/or automated methods for gene synthesis, cloning, and high-throughput screening.](https://figures.cochat.ai/paper-figures/623a08f217244b7cb8bd3e5130040cce/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-1.jpg)

![Fig. 3 Cryo-EM structure of the CTC-445.2–S complex. (A to D) Cryo-EM reconstructions of CTC-445.2 (blue) bound to soluble spike trimers (gray). 3D classification revealed four distinct classes: one CTC-445.2 bound to an “up” RBD (A), two CTC-445.2 bound to two “up” RBDs (B), two CTC-445.2 bound to one “up” and one “down” RBD (C), and three CTC-445.2 bound to two “up” and one “down” RBD (D). (E) Overlay of CTC-445.2-RBD computationally modeled (yellow) and experimentally determined using cryo-EM (blue). The Cα RMSD between the design model and the refined experimental structure is 1.1 Å. (F to H) Comparison of cryo-EM CTC-445.2 (blue), computationally modeled CTC-445.2 (yellow), and hACE2 (green) at the interface of the RBD (gray). (I) Deep mutational scanning heatmap showing the average effect on the enrichment for single site mutants of CTC-445.2 when assayed by yeast display for binding to the SARS-CoV-2 RBD (binding assayed at RBD concentrations of 100, 50, 25, 12.5, 6.25, 3.125, and 1.5625 pM; see the materials and methods). (J) Design model of CTC-445.2 colored by average enrichment at each residue position [from the data in (I)] bound to SARS-CoV-2 RBD (gray). As expected, mutations in the core of the design or to positions involved in binding to the RBD are generally disallowed. The deep mutational scanning revealed that there is still room to further improve the binding affinity of CTC-445.2, including mutations in the binding interface that in principle could afford higher potency and selectivity at the cost of compromising the decoy’s mutational escape resiliency (see Fig. 4).](https://figures.cochat.ai/paper-figures/e55e77c56f884b099aff2cb45d34297d/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-3.jpg)
![Fig. 4 Resilience of CTC-445.2 to SARS-CoV-2 RBD mutational escape. (A) Deep mutational scanning (DMS) of the SARS-CoV-2 RBD interface was performed to assess the effect on binding (by yeast display) to CTC-445.2 (top) or hACE2 (bottom) at eight different concentrations (656, 218, 72, 24, 8, 2, 0.3, and 0.1 nM; fig. S16 and materials and methods). The heatmaps indicate the effect on binding for each possible single amino acid mutation in the hACE2-binding interface of the RBD (see the materials and methods). The results are the average over all the concentrations tested. A black square represents lack of expression in the naive (unselected) library. The color bars at the bottom indicate the secondary structure element with which a given RBD residue interacts: H1, orange; H2, green; EE3, blue; and H4, magenta. Approximately 1700 single mutations were targeted by the experiment. (B) The SARS-CoV-2 RBD surface is colored according to the per-residue-averaged enrichments for binding to CTC-445.2 (top) or hACE2 (bottom). For reference, the structure of CTC-445.2 or ACE2 (respectively) is shown in semitransparent gray cartoons. (C) The 2D scatter plots compare the enrichment values [as in (A)] for the DMS of the RBD binding to CTC-445.2 (y-axis) versus hACE2 (x-axis). There is a high correlation between the effect of RBD mutations in the binding of both molecules, demonstrating the mutational resilience of the de novo decoy (Pearson’s r = 0.92).](https://figures.cochat.ai/paper-figures/ded0c898f59c4bbd8b583f9c8dbd17f3/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-4.jpg)
![Fig. 5 In vitro virus neutralization by CTC-445.2d. (A) Top left: In vitro neutralization of NanoLuc SARS-CoV-2 by CTC-445.2d in Calu-3 cells after 72 hours of incubation at a MOI of 1.0. Top right: A cell viability assay (48 hours) confirmed that the decoys are not cytotoxic to Calu-3. Bottom left: In vitro neutralization of live BetaCoV/Hong Kong/VM20001061/2020 SARS-CoV-2 virus in Vero E6 cells at a MOI of 1.0. The cells were incubated with CTC-445.2d throughout infection and the colors indicate the following: orange, before infection, during infection, and after infection; black, after infection only; and gray, before infection only. SARS-CoV-2 RNA copy numbers were determined by quantitative real-time reverse transcription polymerase chain reaction. All assays were performed in triplicate unless otherwise noted, and all data points are shown. Bottom right: Cell viability in Vero E6 cells was independently performed (CCK8 assay) and it was confirmed that the de novo decoys are not cytotoxic. (B) In vivo mouse pharmacokinetics and tolerability of intranasally administered CTC-445.2d. Left: Plot showing the concentration of fully functional CTC-445.2d (i.e., capable of binding to the SARS-CoV-2 RBD; see the materials and methods) found in homogenized lungs of Balb/c mice after a single 100 μg dose, measured at various times after dosing (n = 5 mice). Right: Body weight of mice after repeat daily intranasal doses of CTC-445.2d (100 μg; n = 18 at day 0) compared with control [phosphate-buffered saline (PBS)–treated] mice (n = 5). At each time point, three CTC-445.2d–treated mice were sacrificed for lung examination. Weight data shown are for the remaining mice (n = 18, 15, 12, 9, 6, and 3 at days 1, 2, 4, 8, 11, and 14, respectively). No significant weight loss or lung abnormalities were observed. Error bars indicate the standard deviation. (C) In vivo Syrian hamster SARS-CoV-2 challenge. Left: Body weight measurements through day 10 for unchallenged hamsters (n = 5, red) compared with SARS-CoV-2–challenged hamsters treated either with a single dose of CTC-445.2d (day 0 at –12 hours; n = 8, orange) or PBS (day –1, day 0 at –12 hours, day 1, and day 2; n = 7, gray). Right: Survival plot. Hamsters were euthanized when they displayed clinical signs of distress according to protocol clinical scoring criteria (see the materials and methods). At the end of the experiment, all hamsters treated with the de novo decoy CTC-445.2d survived, exhibiting moderate weight loss, whereas hamsters treated with vehicle did not survive past day 7 because of severe weight loss and other complications from the viral infection (see table S5).](https://figures.cochat.ai/paper-figures/41c3c064f6944ee9a7976418bd6e3ec3/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SciPy 1.0: fundamental algorithms for scientific computing in Python
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2020) · Nature Methods · doi:10.1038/s41592-019-0686-2 · Cited by 38,430
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
SciPy 1.0: fundamental algorithms for scientific computing in Python
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2019) · Apollo - University of Cambridge Repository · doi:10.17863/cam.64134 · Cited by 10,460
Enzymatic assembly of DNA molecules up to several hundred kilobases
Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison, C. A., & Smith, H. O. (2009) · Nature Methods · doi:10.1038/nmeth.1318 · Cited by 9,996
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,336
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Self-citationStructural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Cell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Self-citationZhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
Scoring function for automated assessment of protein structure template quality
Zhang, Y., & Skolnick, J. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20264 · Cited by 2,392
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia
Chu, D. K. W., Pan, Y., Cheng, S. M. S., Hui, K. P. Y., Krishnan, P., Liu, Y., Ng, D. Y. M., Wan, C. K. C., Yang, P., Wang, Q., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa029 · Cited by 1,278
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,265
Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253
Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,246
Sungnak, W., Huang, N., Bécavin, C., & Berg, M. (2020) · PubMed · Cited by 1,196
How significant is a protein structure similarity with TM-score = 0.5?
Xu, J., & Zhang, Y. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq066 · Cited by 1,142
Belouzard, S., Chu, V. C., & Whittaker, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809524106 · Cited by 1,073
Visualizing density maps with UCSF Chimera
Goddard, T. D., Huang, C. C., & Ferrin, T. E. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.06.010 · Cited by 867
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
Self-citationStructural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.034 · Cited by 776
Why are RNA virus mutation rates so damn high?
Duffy, S. (2018) · PLOS Biology · doi:10.1371/journal.pbio.3000003 · Cited by 752
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Cao, L., Goreshnik, I., Coventry, B., Case, J. B., Miller, L., Kozodoy, L., Chen, R. E., Carter, L., Walls, A. C., Park, Y.-J., et al. (2020) · Science · doi:10.1126/science.abd9909 · Cited by 742
Millet, J. K., & Whittaker, G. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407087111 · Cited by 698
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
Chan, K. K., Dorosky, D., Sharma, P., Abbasi, S. A., Dye, J. M., Kranz, D. M., Herbert, A. S., & Procko, E. (2020) · Science · doi:10.1126/science.abc0870 · Cited by 632
Genetic diversity and evolution of SARS-CoV-2
Phan, T. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104260 · Cited by 627
ter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S. W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 612
De novo design of potent and selective mimics of IL-2 and IL-15
Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature · doi:10.1038/s41586-018-0830-7 · Cited by 531
Self-citationThe SARS-CoV-2 Vaccine Pipeline: an Overview
Chen, W.-H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00201-6 · Cited by 511
Massively parallel de novo protein design for targeted therapeutics
Chevalier, A., Silva, D.-A., Rocklin, G. J., Hicks, D. R., Vergara, R., Murapa, P., Bernard, S. M., Zhang, L., Lam, K.-H., Yao, G., et al. (2017) · Nature · doi:10.1038/nature23912 · Cited by 453
Self-citationAn ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V., Hoppe, N., Boone, M., Billesbølle, C. B., Puchades, C., Azumaya, C. M., et al. (2020) · Science · doi:10.1126/science.abe3255 · Cited by 449
An improved yeast transformation method for the generation of very large human antibody libraries
Benatuil, L., Perez, J. M., Belk, J., & Hsieh, C.-M. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzq002 · Cited by 435
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372
Whitehead, T. A., Chevalier, A., Song, Y., Dreyfus, C., Fleishman, S. J., De Mattos, C., Myers, C. A., Kamisetty, H., Blair, P., Wilson, I. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2214 · Cited by 364
Moderate mutation rate in the SARS coronavirus genome and its implications
Zhao, Z., Li, H., Wu, X., Zhong, Y., Zhang, K., Zhang, Y.-P., Boerwinkle, E., & Fu, Y.-X. (2004) · BMC Evolutionary Biology · doi:10.1186/1471-2148-4-21 · Cited by 286
Immunological mechanism underlying the immune response to recombinant human protein therapeutics
Sauerborn, M., Brinks, V., Jiskoot, W., & Schellekens, H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.001 · Cited by 207
Ettinger, M. P., Littlejohn, T. W., Schwartz, S. L., Weiss, S. R., McIlwain, H. H., Heymsfield, S. B., Bray, G. A., Roberts, W. G., Heyman, E. R., Stambler, N., et al. (2003) · JAMA · doi:10.1001/jama.289.14.1826 · Cited by 205
De novo protein design enables the precise induction of RSV-neutralizing antibodies
Sesterhenn, F., Yang, C., Bonet, J., Cramer, J. T., Wen, X., Wang, Y., Chiang, C.-I., Abriata, L. A., Kucharska, I., Castoro, G., et al. (2020) · Science · doi:10.1126/science.aay5051 · Cited by 191
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181
A fully automatic method yielding initial models from high-resolution cryo-electron microscopy maps
Terwilliger, T. C., Adams, P. D., Afonine, P. V., & Sobolev, O. V. (2018) · Nature Methods · doi:10.1038/s41592-018-0173-1 · Cited by 170
D614G mutation of SARS-CoV-2 spike protein enhances viral infectivityPreprint
Hu, J., He, C., Gao, Q., Zhang, G., Cao, X., Long, Q., Deng, H., Huang, L., Chen, J., Wang, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.20.161323 · Cited by 162
Self-citationMolecular Basis of Coronavirus Virulence and Vaccine Development
Enjuanes, L., Zuñiga, S., Castaño-Rodriguez, C., Gutierrez-Alvarez, J., Canton, J., & Sola, I. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.003 · Cited by 159
Immunogenicity of recombinant human proteins: causes and consequences
Schellekens, H., & Casadevall, N. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1202-9 · Cited by 158
Erythropoietin gene therapy leads to autoimmune anemia in macaques
Gao, G., Lebherz, C., Weiner, D. J., Grant, R. L., Calcedo, R., McCullough, B. A., Bagg, A., Zhang, Y., & Wilson, J. M. (2003) · Blood · doi:10.1182/blood-2003-11-3852 · Cited by 155
Complete mapping of viral escape from neutralizing antibodies
Doud, M. B., Hensley, S. E., & Bloom, J. D. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006271 · Cited by 142
Principles for designing proteins with cavities formed by curved β sheets
Marcos, E., Basanta, B., Chidyausiku, T. M., Tang, Y., Oberdorfer, G., Liu, G., Swapna, G. V. T., Guan, R., Silva, D., Dou, J., et al. (2017) · Science · doi:10.1126/science.aah7389 · Cited by 140
Self-citationStrauch, E.-M., Bernard, S. M., La, D., Bohn, A. J., Lee, P. S., Anderson, C. E., Nieusma, T., Holstein, C. A., Garcia, N. K., Hooper, K. A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3907 · Cited by 119
Self-citationImmunogenicity and other problems associated with the use of biopharmaceuticals
Tovey, M. G., & Lallemand, C. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611406318 · Cited by 108
Coronaviruses as DNA Wannabes: A New Model for the Regulation of RNA Virus Replication Fidelity
Smith, E. C., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003760 · Cited by 107
Zhou, J., Panaitiu, A. E., & Grigoryan, G. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908723117 · Cited by 97
Treatment of type 2 diabetes with the designer cytokine IC7Fc
Findeisen, M., Allen, T. L., Henstridge, D. C., Kammoun, H., Brandon, A. E., Baggio, L. L., Watt, K. I., Pal, M., Cron, L., Estevez, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1601-9 · Cited by 86
Essentials of de novo protein design: Methods and applications
Marcos, E., & Silva, D. (2018) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1374 · Cited by 63
Self-citationMinami, S., Sawada, K., & Chikenji, G. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-24 · Cited by 61
Koday, M. T., Nelson, J., Chevalier, A. A., Koday, M., Kalinoski, H. M., Stewart, L. J., Carter, L. P., Nieusma, T., Lee, P. S., Ward, A. B., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005409 · Cited by 58
Self-citationMotif-Driven Design of Protein–Protein Interfaces
Silva, D., Correia, B. E., & Procko, E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3569-7_17 · Cited by 58
Self-citationSybodies targeting the SARS-CoV-2 receptor-binding domainPreprint
Walter, J. D., Hutter, C. A. J., Zimmermann, I., Wyss, M., Egloff, P., Sorgenfrei, M., Hürlimann, L. M., Gonda, I., Meier, G., Remm, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.16.045419 · Cited by 58
Schoof, M., Faust, B., Saunders, R. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.08.238469 · Cited by 49
The advent of de novo proteins for cancer immunotherapy
Quijano‐Rubio, A., Ulge, U. Y., Walkey, C., & Silva, D. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.002 · Cited by 41
Self-citationFactors that contribute to the immmunogenicity of therapeutic recombinant human proteins
Mukovozov, I., Sabljic, T. F., Hortelano, G., & Ofosu, F. A. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-11-0654 · Cited by 36
Structures and disulfide cross‐linking of de novo designed therapeutic mini‐proteins
Silva, D., Stewart, L. J., Lam, K. H., Jin, R., & Baker, D. A. (2018) · FEBS Journal · doi:10.1111/febs.14394 · Cited by 13
Self-citation
Research works printed but not linked: 1
- National Center for Biotechnology Information “VAST: Non-redundant PDB chain set” (2016); https://structure.ncbi.nlm.nih.gov/Structure/VAST/nrpdb.html.
Cited by
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Chen, J., Wang, R., Gilby, N. B., & Wei, G.-W. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01451 · Cited by 653
Self-citationCircular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
“It has been reported that SARS-CoV-2 neutralizing nanobodies or 190 hACE2 decoys could inhibit the SARS-CoV-2 infection (54-56).”
Scaffolding protein functional sites using deep learning
Wang, J., Lisanza, S., Juergens, D., Tischer, D., Watson, J. L., Castro, K. M., Ragotte, R., Saragovi, A., Milles, L. F., Baek, M., et al. (2022) · Science · doi:10.1126/science.abn2100 · Cited by 487
“As a test case, we scaffolded the helix of human angiotensin-converting enzyme 2 (hACE2) interacting with the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (29).”
MethodDeep generative molecular design reshapes drug discovery
Zeng, X., Wang, F., Luo, Y., Kang, S.-G., Tang, J., Lightstone, F. C., Fang, E. F., Cornell, W., Nussinov, R., & Cheng, F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100794 · Cited by 295
“65 Deep generative models can also be used to design protein therapies by modeling the spatial properties of the amino acid sequence.”
BackgroundDeveloping therapeutic approaches for twenty-first-century emerging infectious viral diseases
Meganck, R. M., & Baric, R. S. (2021) · Nature Medicine · doi:10.1038/s41591-021-01282-0 · Cited by 252
Self-citation
Metadata
- Authors
- Linsky, T. W., Vergara, R., Codina, N., Nelson, J. W., Walker, M. J., Su, W., Barnes, C. O., Hsiang, T.-Y., Esser-Nobis, K., Yu, K., Reneer, Z. B., Hou, Y. J., Priya, T., Mitsumoto, M., Pong, A., Lau, U. Y., Mason, M. L., Chen, J., Chen, A., Berrocal, T., Peng, H., Clairmont, N. S., Castellanos, J., Lin, Y.-R., Josephson-Day, A., Baric, R. S., Fuller, D. H., Walkey, C. D., Ross, T. M., Swanson, R., Bjorkman, P. J., Gale, M., Blancas-Mejia, L. M., Yen, H.-L., & Silva, D.-A.
- Affiliations
- Neoleukin Therapeutics (United States) (US)
- Neoleukin Therapeutics Inc., Seattle, WA, USA.
- University of Hong Kong (HK)
- California Institute of Technology (US)
- University of Washington (US)
- Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, USA.
- University of Georgia (US)
- University of North Carolina at Chapel Hill (US)
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
- Corresponding author
- Linsky, Thomas W.
- Vergara, Renan
- Nelson, Jorgen W.
- Silva, Daniel-Adriano
- ORCID
- Linsky, Thomas W.
- Vergara, Renan
- Codina, Nuria
- Nelson, Jorgen W.
- Walker, Matthew J.
- Su, Wen
- Barnes, Christopher O.
- Hsiang, Tien-Ying
- Esser-Nobis, Katharina
- Yu, Kevin
- Reneer, Z. Beau
- Hou, Yixuan J.
- Mitsumoto, Masaya
- Lau, Uland Y.
- Mason, Marsha L.
- Chen, Jerry
- Chen, Alex
- Berrocal, Tania
- Peng, Hong
- Josephson-Day, Anna
- Baric, Ralph S.
- Fuller, Deborah H.
- Walkey, Carl D.
- Ross, Ted M.
- Swanson, Ryan
- Bjorkman, Pamela J.
- Gale, Michael
- Blancas-Mejia, Luis M.
- Yen, Hui-Ling
- Silva, Daniel-Adriano
- Venue
- Science
- Published
- 2020-12-04
- Volume
- 370
- Issue
- 6521
- Pages
- 1208-1214
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7920261
- OpenAlex
- W3096331199
- Cited by
- 216
- References
- 72
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 12 · 2023: 33 · 2022: 50 · 2021: 92 · 2020: 10
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- PubMed Central (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (AI145296, AI127463, R01AI108197)
- National Institute of Allergy and Infectious Diseases (HHSN272201400006C)
- Georgia Research Alliance (GRA-001)
- Neoleukin (UGA-002)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- SARS-CoV-2, de novo protein design, spike protein receptor-binding domain, neutralizing antibodies, decoy receptor, host-directed antiviral therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.